This inventor holds 1 USPTO granted patent. Top assignee: Avant Immunotherapeutics, Inc.. Active years: 2002.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2002
Title: David Beattie: Innovator in Enterococcus faecalis Research
Introduction
David Beattie is a notable inventor based in Roslindale, MA (US). He has made significant contributions to the field of microbiology, particularly in the study of Enterococcus faecalis. His work has implications for understanding bacterial behavior and developing therapeutic strategies.
Latest Patents
David Beattie holds a patent for the IVI-2, IVI-3, and IVI-4 loci of Enterococcus faecalis polynucleotide, polypeptides, and methods of use therefor. This invention provides polynucleotides coding for the mature transcriptional regulators known as ivi-2 and ivi-3, as well as a polynucleotide coding for a polypeptide designated as ivi-4. The polynucleotides were obtained from a genomic library derived from the bacterial species.
Career Highlights
David Beattie is associated with Avant Immunotherapeutics, Inc., where he has been instrumental in advancing research related to immunotherapy and bacterial genetics. His innovative work has the potential to influence future treatments and understanding of bacterial infections.
Conclusion
David Beattie is a prominent figure in the field of microbiology, with a focus on Enterococcus faecalis. His patent reflects his dedication to advancing scientific knowledge and therapeutic applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile